Objectives: Bombesin receptor subtype-3 (BRS-3) has been suggested to play a potential role in energy homeostasis. However, the physiological mechanism of BRS-3 on energy homeostasis remains unknown. Thus, we investigated the BRS-3-mediated neuronal pathway involved in food intake and energy expenditure.
| INTRODUCTION
The central nervous system (CNS) plays an important role in energy homeostasis. The disruption of this system leads to the dysregulation of feeding behavior and energy metabolism, which is associated with obesity. Obesity contributes to the development of a large number of diseases, including diabetes mellitus, hypertension, coronary heart disease, and certain types of cancer and hence remains an important social problem (Guh et al., 2009; Pi-Sunyer, 2009 ). Although several anti-obesity agents are in the market, their efficacy is limited (Butsch, 2015) . Therefore, research on CNS-acting drugs with regulatory effects on both feeding behavior and peripheral energy metabolism could represent a potential strategy for developing potent anti-obesity drugs.
Bombesin-like peptides are known to serve as neuromodulators in the CNS. Bombesin was originally isolated from the skin of frogs as a 14-amino acid peptide with smooth muscle contraction activity; thereafter, several bombesin-like peptides were identified from various species. There are two such peptides in mammals, gastrinreleasing peptide (GRP) and neuromedin B (NMB), which bind to the G-protein-coupled receptors (GPCR) GRP receptor (GRPR) and NMB receptor (NMBR), respectively (Corjay et al., 1991; Ramos-Álvarez et al., 2015; Whitley, Moore, Giraud, & Shulkes, 1999) . Bombesin receptor subtype-3 (BRS-3) was identified as the third member of this GPCR subfamily, based on sequence similarity, and was found to be expressed in the CNS (Fathi et al., 1993) . However, despite the sequence similarity, BRS-3 does not have a high affinity with any known bombesin-like peptides, and its natural ligand remains unknown (Ramos-Álvarez et al., 2015) . Although the physiological function of BRS-3 remains unclear, BRS-3-deficient (Brs-3 -/Y ) mice are known to develop obesity and have a reduced metabolic rate and increased food intake (FI) (Guan et al., 2010; Ladenheim et al., 2008; Ohki-Hamazaki et al., 1997; Yamada, Santo-Yamada, Wada, & Wada, 2002) . Several nonpeptide BRS-3 agonists with an antiobesity effect in animals have recently been developed (Chobanian et al., 2012; Guan et al., 2010 Guan et al., , 2011 Lateef, Abreu-Vieira, Xiao, & Reitman, 2014; Matsufuji et al., 2015; Metzger et al., 2010; Sebhat et al., 2011) . In particular, Guan et al. reported that Bag-1, a potent and selective small-molecule BRS-3 agonist, increased the fasting metabolic rate and body temperature and reduced the FI and body weight (BW) in mice. These results suggest that BRS-3 might serve as an attractive drug target for treating obesity .
Feeding and energy metabolism are regulated by the neural network of central and peripheral nervous systems, in which the hypothalamus plays a central role. The neurons in the hypothalamus receive inputs from the periphery through the brain stem and from the midbrain and cortex, which subsequently integrate the information associated with the energy status (Waterson & Horvath, 2015) .
In this neural network, the arcuate nucleus (ARC), paraventricular hypothalamic nucleus (PVH), ventromedial nucleus of the hypothalamus, and dorsomedial nucleus of the hypothalamus (DMH) play important roles with the help of multiple hypothalamic peptides (van Swieten, Pandit, Adan, & van der Plasse, 2014; Waterson & Horvath, 2015) .
For instance, neuropeptide Y (NPY), agouti-related peptide (AgRP), orexin, and melanin-concentrating hormone (MCH) induce hyperphagia, whereas α-melanocyte-stimulating hormone (α-MSH), oxytocin, corticotropin-releasing hormone (CRH), and arginine vasopressin (AVP) induce anorexia (Crespo, Cachero, Jiménez, Barrios, & Ferreiro, 2014) . These peptides are also involved in the control of peripheral energy expenditure (EE) through the sympathetic nervous system.
Furthermore, the preoptic area is known to represent the center of autonomic thermoregulation and is involved in peripheral EE via the DMH and brainstem (Morrison, 2016) . As BRS-3 is reportedly expressed in the hypothalamus (Jennings et al., 2003; Liu et al., 2002; Sano et al., 2004; Zhang et al., 2013) , it is expected to regulate energy homeostasis through this hypothalamic neural network. Nevertheless, the precise neural pathway underlying the BRS-3 agonist-mediated anti-obesity effect remains unclear.
Recently, we reported a novel selective nonpeptide BRS-3 agonist, compound-A (Nio et al., 2017) . Compound-A shows clear anorectic effects and enhanced energy expenditure in rats, suggesting that this compound is an useful tool compound to assess the function of BRS-3
neurons. Thus, in this study, we examined the hypothalamic neural network underlying the BRS-3-expressing neuron-mediated energy homeostasis regulation using compound-A.
| MATERIALS AND METHODS

| Compounds
Compound-A (active conformer (tR2(IC)), 6-benzyl-N-tert-butyl-9-met hoxy-7-oxo-6,7-dihydro-5H-dibenzo[c,e]azepine-5-carboxamide) and compound-C (racemate) were synthesized at Takeda Pharmaceutical Company Limited as previously reported (Nio et al., 2017) . Sibutramine and CL316,243 were purchased from Wako Pure Chemical (Osaka, Japan) and Tocris Bioscience (Bristol, UK), respectively. The compounds were suspended in 0.5% methylcellulose solution for oral dosing.
| Animals
F344/Jcl rats (male, 5-week-old) were purchased from CLEA Japan (Tokyo, Japan). They were fed on a high-fat diet (HFD; D12451:
Research Diets, NJ, USA) from the age of 5 weeks to achieve dietinduced obesity (DIO). Male Sprague Dawley (SD) rats were also purchased from CLEA Japan. 
| In vitro agonistic activity
With regard to functional assays, the agonist-induced mobilization of intracellular Ca 2+ was measured in CHO-K1 cells that overexpressed BRS-3 using an aequorin bioluminescence assay (duplicate experiments).
| Pharmacokinetic parameters of compound-A in SD rats
To determine the pharmacokinetic parameters of compound-A, male 8-week-old SD rats (n = 3) were orally administered certain compounds (1 mg/kg BW/5 ml, suspended in 0.5% methylcellulose aqueous solution) via cassette dosing. The plasma compound concentrations were measured using liquid chromatography-tandem mass spectrometry.
| Measurement of FI and BW after compound-A administration in SD or DIO-F344 rats
Male SD rats (10-week-old) were divided into five groups (4-5 rats in each group) based on the nocturnal FI during the previous night and the BW on the morning of the drug administration. The SD rats were orally administered with vehicle (0.5% methylcellulose solution), compound-C (3, 10, and 30 mg/kg), or sibutramine (10 mg/kg) at 1-2 hr prior to the onset of the dark phase. FI was measured 24 hr after drug administration, whereas BW was measured 24 hr after drug administration. Two weeks before the study, DIO-F344 rats were fed on a powdery HFD and had been acclimatized to oral dosing. The DIO-F344 rats (male, 47-, 52-or 53-week-old) were divided into four or five groups (4-8 rats in each group) based on the nocturnal FI during the previous night and the BW on the morning of the drug administration. The DIO-F344 rats were orally administered with vehicle (0.5% methylcellulose solution), compound-A or compound-C (3, 10, and 30 mg/kg), or sibutramine (1 mg/kg) at 1-2 hr prior to the onset of the dark phase. FI was measured 4, 16, and 24 hr after drug administration, whereas BW was measured 24 hr after drug administration.
| Measurement of EE after compound-A administration in fasted DIO-F344 rats
DIO-F344 rats (male, 57-week-old) underwent fasting for 16 hr and were then housed individually in the metabolic chamber of an
Oxymax system (Columbus Instructions, OH, USA) for acclimatization to the chamber. The rats were divided into three groups according to the BW and EE at approximately 10 a.m. for 1 hr. At 11:00 a.m., the rats were orally administered with vehicle (0.5% methylcellulose solution), compound-A (30 mg/kg), or CL316,243
(2 mg/kg), and the heat production and respiratory exchange ratio (RER) were measured over 5 hr with 10-min interval. Data were averaged in every 30 min. from 6 weeks of age and were acclimatized to oral dosing for 1 week.
| Effect of compound-A on FI and BW in
They were divided into three groups according to the nocturnal FI of the previous day and the BW on the morning of the day of drug administration. They were orally administered vehicle (0.5% methylcellulose solution), compound-A (100 mg/kg), or sibutramine (10 mg/kg).
The FI and BW were measured at 16 and 24 hr after drug administration, respectively.
| Histochemistry
To determine the expression of BRS-3 mRNA and feeding-related neuropeptides, brain samples from adult male SD rats (7-week-old)
were examined. and then treated with CSA II (DAKO Japan, K149711, Kyoto, Japan) to enhance the FITC signal.
After processing, the sections were mounted and then examined via light microscopy or confocal laser microscopy.
| Antibodies
Primary antibodies used in this study are listed in Table 1 . We used two different anti-c-Fos antibodies, Santa Cruz Biotechnology sc-52 and sc-253. sc-52 recognized the predicted molecular weight of 62 kDa on Western blots (manufacturer's datasheet), and it has been validated for detection of nuclear-localized c-Fos proteins (Brown, Gentry, & Rowland, 1998) . sc-253 was used for immunostaining after ISH reaction. This antibody recognized the predicted molecular weight of 62 kDa on Western blots (manufacturer's datasheet) and it has been validated for detection of nuclear-localized c-Fos proteins (Konsman & Blomqvist, 2005) . For the marker of oxytocin-containing neuron, anti-oxytocin antibody (Calbiochem, PC226L) was used.
Staining is completely eliminated by pretreatment of antibody with
oxytocin, but no staining is detected by pre-absorption of antibody with vasopressin (manufacturer's datasheet). This antibody has been validated for detection of cell bodies and fibers in oxytocin mRNA localized nucleus, such as PVH and supraoptic nucleus (Luo, Kaur, & Ling, 2002) . For the marker of AVP-containing neuron, anti-AVP antibody (Phoenix, H-065-07) was used. This antibody does not react with oxytocin (manufacturer's datasheet) and it has been validated for detection of cell bodies and fibers in AVP-mRNA localized nucleus, such as PVH and supraoptic nucleus (Yi et al., 2008) .
| Quantitative analysis of the images
To avoid overcounting, evenly spaced series of sections (80-or 120-μm interval) including regions of interest (ROIs) were prepared and stained. The sections for PVH, DMH, medial preoptic area (MPA), ARC, and NTS were dissected from the areas including bregma −1.0 to −2.3, −2.2 to −3.5, −0.2 to −1.0, −1.8 to −4.2, and −13.7 to −14.3 mm, respectively (Paxinos & Watason, 2004) .
After sections at both end of ROI were removed, two to four sections in each animal were selected and the 0.58-or 0.29-mm 2 images, including the unilateral nucleus, were acquired using Nikon ECLIPSE E800 (two images were obtained from one section). The (2008) c-Fos-positive cells in the BRS-3 mRNA-positive neurons were calculated from the acquired 0.29-mm 2 images; two to four sections 
| Quantitative reverse transcriptase (RT)-PCR of peptides in the brain regions of DIO-F344 rats after compound-A administration
DIO-F344 rats (male, 53-week-old) were orally administered vehicle (0.5% methylcellulose solution) or compound-A (30 mg/kg) at 9:00 a.m. following fasting for 16 hr or under free access food and water conditions. At 1 hr after dosing, the rats were anesthetized, and the samples including ARC, PVH, lateral hypothalamic area (LHA), or nucleus tractus solitarius (NTS) were dissected. In detail, 1 mm of brain slices was prepared using Brain Matrix (Muromachi Kicai, BS-Z 2000C, Tokyo, Japan), and then, the area including ROI was roughly dissected by razors. Total RNA was extracted using ISOGEN (Nippon Gene, Tokyo, Japan), and then, cDNA was prepared from total RNA by oligo (dT) primer using SuperScript II reverse transcriptase (Invitrogen).
Expression analysis (TaqMan RT-PCR) was performed by ABI Prism 7900HT (Applied Biosystems, MA, USA) using TaqMan ® Gene
Expression Master Mix (Applied Biosystems), with the primers and probes listed in Table 2 . For rat cyclophilin, predesigned primers and probe (Rn00452692_m1; Assays-on-Demand, Applied Biosystems)
were used. The mRNA expression in each gene was normalized to the cyclophilin mRNA expression using ddCT method.
| Statistical analysis
Data involving more than two groups were assessed by one-way analysis of variance (ANOVA) 
| RESULTS
| Profile of the BRS-3 agonist compounds
Compound-A is an active conformer (tR2(IC)) of BRS-3 agonist as previously reported (Nio et al., 2017 ). The pharmacokinetic profile of compound-A (1 mg/kg, po) in SD rats was determined and the maximum plasma concentration (Cmax), time at which the Cmax was observed (Tmax), and bioavailability (BA) were found to be 69.1 ng/ml, 0.5 hr, and 21.7%, respectively. Our previous study revealed that the compound-C can pass the blood-brain barrier,
suggesting that compound-A could pass the blood-brain barrier (Nio et al., 2017) .
| Anti-obesity effect of single oral administration of compound-A in DIO-F344 rats
We examined the effect of compound-A and compound-C on the 
| Distribution of BRS-3 mRNA in the adult rat brain
To demonstrate the localization of BRS-3 mRNA within the CNS, we performed an ISH study in adult SD rat brains. ISH was performed using a rat BRS-3 cRNA probe in coronal sections and showed specific signals for the antisense probe on cell cytoplasm in a wide range of (Figure 3g ), where the number of orexigenic NPY and anorexigenic POMC mRNA-positive neurons was less as compared to those in the anterior part in our ISH study (Figure 4d ,e). These data were similar to the results of a previous study on BRS-3 mRNA distribution in the CNS of rats and mice (Liu et al., 2002; Zhang et al., 2013) . The data are summarized in Table 3 .
| Localization of feeding-relating neuropeptides in BRS-3 mRNA-positive neurons
Neurons in the PVH and ARC secrete several neuropeptides that regulate feeding behavior, such as CRH, oxytocin, AVP, NPY, and α-MSH processed from POMC. We performed double staining of BRS-3 mRNA with these peptides in adult SD rats to demonstrate their colocalization. Oxytocin and AVP were detected using IHC, whereas CRH, NPY, and POMC were examined using ISH. In the PVH, F I G U R E 2 Enhancement of energy expenditure by compound-A in fasted DIO-F344 rats. (a, b) Heat production (kcal/hr/rat) (a) and respiratory exchange ratio (RER) (b) were measured after single oral administration of compound-A (30 mg/kg) and CL316,243 (2 mg/kg) for 270 min. BW of vehicle, compound-A, and CL316,243-administered rats was 492.6 ± 10.7, 494.1 ± 22.0, and 480.7 ± 20.0 g, respectively (mean values ± standard deviation). Results are presented as mean values ± standard deviation (n = 5, CL316,243 2 mg/kg: n = 3). *p < .05 versus vehicle (Student's t test followed by Bonferroni's correction for 9-time point comparisons) F I G U R E 3 Distribution of BRS-3 mRNA in the rat CNS. (a-i) Coronal rat brain sections were stained with a rat BRS-3 antisense cRNA probe. Results and abbreviations are summarized in Table 3 . Bar: 500 μm (a-c, g), 250 μm (d-f, h, i). 3v, 3rd ventricle; ac, anterior commissure; d3v, dorsal 3rd ventricle; mt, mammillothalamic tract; lv, lateral ventricle; och, optic chiasm; scp, superior cerebellar peduncle 
| Induction of c-Fos proteins in the BRS-3 mRNA-positive neurons following refeeding
Refeeding-induced satiety is considered to activate anorexigenic neurons. To clarify the BRS-3-expressing neurons involved in feeding suppression, adult SD rats were subjected to a 48-hr fasting;
at 2 hr after refeeding, the distribution of c-Fos-ir neurons in the hypothalamus was evaluated using IHC. In our experimental condi- (Figure 6n ). T A B L E 3 Distribution of BRS-3 mRNA in the rat central nervous system of c-Fos in the BRS-3 neurons was slightly, but significantly, increased after compound-A administration (Figure 8j-l) .
| Induction of c-Fos proteins in BRS-
| Anorexigenic effect of BRS-3 agonist in
A previous study showed that expression of MCH and its receptor mRNA was increased in the hypothalamus of BRS-3 -/Y mice (Maekawa, Quah, Tanaka, & Ohki-Hamazaki, 2004) . Thus, the antiobesity effect of BRS-3 agonist was considered to be mediated via the MCH pathway. As we have shown the anti-obesity effect of compound-A in mice (Nio et al., 2017) , compound-A can be used for mouse studies. Then, we attempted to validate this hypothesis using HFD-fed Mchr1 −/− mice and HFD-fed wild-type mice. In addition to sibutramine (10 mg/kg), single oral administration of compound-A (100 mg/kg) significantly decreased the FI and BW in both wild-type mice and Mchr1−/− mice (Figure 9a-d) .
| Effect of compound-A on feeding-relating peptide gene expression in the brain of DIO-F344 rats
To clarify the pathophysiological role of BRS-3 on the FI in the rat brain, we measured the gene expression of feeding-relating peptides , Cart, Npy, Agrp, Hcrt, Pmch, Crh, Oxt, Avp, and Bdnf (listed in 
Pomc
| DISCUSSION
In this study, we examined the hypothalamic neuronal pathway underlying energy homeostasis regulation by BRS-3-expressing neurons using compound-A as a tool compound. Compound-A is a novel orally available, selective, small-molecule BRS-3 agonist that we have recently reported (Nio et al., 2017) . The in vivo specificity of compound-A to BRS-3 has been shown using BRS-3-deficient mice (Nio et al., 2017) . In addition to our previous study, this study showed that the single oral administration of compound-A reduced the FI and BW in DIO-F344 rats and increased the EE in fasted DIO-F344 rats (Figures 1   and 2 ). Thus, this compound can be used for analyzing the mechanism of BRS-3-expressing neuron-mediated energy homeostasis under single oral administration. 
Strong BRS-3 mRNA signals were observed in the PVH, DMH, and MPA in the hypothalamus (Figure 3 ) (Jennings et al., 2003; Liu et al., 2002; Sano et al., 2004; Zhang et al., 2013) . Hence, we focused on the neurons in these nuclei. c-Fos, an immediate early gene, was used to map the neural activation following stimuli (Sakuma et al., 2015) . Under our experimental conditions, refeeding was found to activate the neu- Richard, 2002; Wu et al., 2014; Zséli et al., 2016) . These data suggest that neurons in the PVH and DMH are critical for satiety regulation.
The PVH plays an important role in the regulation of numerous physiological processes, including feeding and energy metabolism (Seoane-Collazo et al., 2015; van Swieten et al., 2014) and is roughly divided into two parts: PVHm and PVHp. The neurons in the PVHm mainly contain oxytocin and AVP, whereas those in the PVHp mainly contain CRH and TRH; these peptides suppress feeding behavior.
TRH neurons in PVH are also reported to have orexigenic function . Previous reports have indicated that refeeding mainly activates the AVP-positive neurons in the PVHm and CRHpositive neurons in the PVHp (Timofeeva et al., 2005) . However, we found that the BRS-3-expressing neurons in the PVH did not contain CRH, oxytocin, or AVP (Figure 4) . Although this is different from the previous reports that only a few CRH-and oxytocin-positive neurons overlap with BRS-3 (Bagnol & Grottick, 2008; Zhang et al., 2013) , it is obvious that most of the BRS-3 neurons in PVH do not contain CRH and oxytocin. Nevertheless, refeeding activated ~80% of the BRS-3-expressing neurons in the PVHp ( Figure 6 ) and these neurons were activated by compound-A at the dose showing anorexigenic efficacy (Figure 8 ). These data suggest that BRS-3-expressing neurons in the PVH are mainly involved in the anorexigenic action of compound-A.
Furthermore, the cluster of neurons expressing BRS-3 was localized ventrally to the normal distribution of typical neuropeptide-containing neurons in the PVH (Figure 4f) . Thus, the cluster of BRS-3-expressing neurons in the PVHp could represent a novel subdivision in the PVH that plays an important role in feeding behavior through an unknown mechanism. Recently, MC4R-expressing glutamatergic neurons in the PVH were reported to regulate feeding without any colocalization with oxytocin, CRH, AVP, or prodynorphin (Balthasar et al., 2005; Garfield et al., 2015; Shah et al., 2014) . BRS-3 expression in this neural population should be revealed in the future. Moreover, compound-A elicits c-Fos induction in non-BRS-3-expressing neurons in the PVH (data not shown), which suggests that BRS-3 agonists could indirectly activate these PVH neurons. This indirect PVH activation can be mediated through BRS-3-expressing neurons in other nuclei (such as in the LPB) that project to the PVH (Zséli et al., 2016) .
Refeeding activated the neurons in the DMH (Figure 5 ), but the number of refeeding-activated BRS-3-expressing neurons was ~20%
( Figure 6 ). Hence, most of the BRS-3-expressing neurons in the DMH are not involved in refeeding-induced satiety. The DMH is known to be closely involved in various functions, including feeding behavior, thermoregulation, circadian rhythm, cardiovascular function, locomotor activity, stress, and reproduction (Lo et al., 2016; Morrison, 2016; van Swieten et al., 2014) . The regulatory role of the DMH in energy homeostasis is well established in lesion studies, and leptin is known to directly activate neurons in the DMH (Bellinger & Bernardis, 2002; van Swieten et al., 2014) . Recently, Garfield et al. reported that leptin receptorexpressing GABAergic DMH neurons (ventral compartment) play an important role for suppression of ARC AgRP neurons (Garfield et al., 2016) . The refeeding-sensitive BRS-3-expressing neurons in the DMH might belong to this feeding-relating neuronal cluster. roles in thermoregulation (Morrison, 2016) . Thermal sensory inputs are integrated in the preoptic area, including the MPA and MnPO, and are transmitted to the DMH, rostral raphe pallidus, and preganglionic sympathetic neurons. Previous reports have shown that BRS-3 agonist regulates body temperature, blood pressure, and heart rate via a central sympathetic mechanism (Lateef et al., 2014 (Lateef et al., , 2016 Metzger et al., 2010) . As Bagnol et al. have reported that ~80% of BRS-3-expressing neurons in the MPA and ventromedial preoptic nucleus are GABAergic (Bagnol & Grottick, 2008) , the BRS-3-expressing neurons in the MPA could play an important role in energy metabolism through the sympathetic nerve. Intriguingly, neurons in the DMH are known to mediate the MPA-induced thermogenic regulation in brown adipose tissue and are considered as thermogenesis-promoting neurons (Morrison, 2016) . Hence, the activation of BRS-3 neurons in the DMH by compound-A could lead to peripheral EE enhancement through this sympathetic pathway. However, the thermogenesis-promoting neurons in the DMH are inhibited by GABAergic neurons in the MPA. Thus, it is less likely that the BRS-3-expressing GABAergic neurons in the MPA project to the DMH. One possibility is that BRS-3 is expressed in GABAergic interneurons in the MPA or MnPO, which inhibit the neurons in the MPA that project to the DMH. Hence, the regulatory mechanism underlying EE in BRS-3 neurons needs to be investigated further.
The ARC plays a key role in energy homeostasis (Seoane-Collazo et al., 2015; van Swieten et al., 2014) . It possesses orexigenic NPY/ AgRP neurons and anorexigenic POMC/CART neurons. However, BRS-3-expressing neurons in the ARC did not exhibit Npy or Pomc mRNA signals (Figure 4) , consistent with previous studies (Zhang et al., 2013) .
In our experimental condition, refeeding did not induce c-Fos expression in the ARC ( Figure 5 ) and compound-A administration induced only slight c-Fos induction in BRS-3-expressing neurons ( Figure 8 ). As previous study showed that refeeding significantly leads to c-Fos induction in ARC (Wu et al., 2014) , the lack of c-Fos induction in this study was due to the difference of experimental condition. In addition, it would be supposed that limited c-Fos induction by compound-A might be due to potent inhibitory regulation to these neurons. Hence, the involvement F I G U R E 1 0 Effect of compound-A on feeding-relating peptide gene expression in the brain of DIO-F344 rats. DIO-F344 rats under ad libitum (Ad lib) conditions were fasted for 16 hr (Fast) and then orally administered with vehicle or compound-A (30 mg/kg). At 1 hr after dosing, the brain samples were dissected and mRNA level listed in Table 2 that regulate EE (Kong et al., 2012) . Moreover, Bagnol et al. reported that approximately 80% of the BRS-3-expressing neurons in the posterior ARC are GABAergic (Bagnol & Grottick, 2008) . Thus, it is likely that BRS-3 neurons in the ARC may be involved in EE enhancement.
Although we focused on hypothalamic regulation by the BRS-3 agonist, there are several extrahypothalamic nuclei where BRS-3 is strongly expressed, such as in the LPB and MHb (Figure 3) . LPB reportedly works as a hub that integrates signals from several brain regions to modulate feeding and BW (Wu, Boyle, & Palmiter, 2009; Wu, Clark, & Palmiter, 2012) . LPB also reportedly mediates the transmission signals from cutaneous thermoreceptors in thermoregulation (Morrison, 2016) . Furthermore, MHb plays an important role in stress, memory, and nicotine withdrawal, and has a neural connection with the LHb that is related to the reward and aversion functions (Meye, Lecca, Valentinova, & Mameli, 2013; Viswanath, Carter, Baldwin, Molfese, & Salas, 2013) . Thus, LPB and MHb could be involved in the anti-obesity effect of the BRS-3 agonist. Nevertheless, further study on the extrahypothalamic regulation by BRS-3 agonist is needed.
The anti-obesity effect of the BRS-3 agonist was still reportedly observed in Npy−/−, Mc4r−/−, Cb1r−/−, and Lepr−/− mice (Guan et al., 2010) . Moreover, we found that the anti-obesity effect by compound-A was not changed in Mchr1 −/− mice ( Figure 9 ) and MCH expression was unchanged after compound-A administration (Figure 10 ).
Bagnol. et al. has reported that no BRS-3 mRNA expression is observed in the LHA MCH neurons (Bagnol & Grottick, 2008) , and thus, it is likely that MCH pathway is not important for BRS-3-mediated energy regulation. These results strongly support our hypothesis that the well-known feeding-related peptides are not the primary regulators involved in the anti-obesity effect mediated by the BRS-3-expressing neurons. On the other hand, we found a significant change in the expression of Pomc mRNA in the ARC and Cart mRNA in the ARC, LHA, and NTS as a result of compound-A administration (Figure 10 ).
Hence, these peptides could lead to at least partial energy regulation by BRS-3, whereas we observed a compound-A-induced increase of Npy mRNA, a potent orexigenic peptide, in ARC ( Figure 10 ). As it is clear that BRS-3 agonist finally exerts anti-obesity effects, this NPY increase might be a compensatory reaction. Regarding this controversy, further investigation is needed.
This study has certain limitations. As only acute responses in the CNS were examined, we cannot exclude the possibility that the chronic responses of BRS-3-expressing neurons associated with energy homeostasis would differ from our results. Moreover, even in the hypothalamus, there are areas that have not been examined, such as BRS-3-expressing neurons in the SCN. SCN may be involved in the BRS-3 agonist-mediated anti-obesity effect via circadian rhythm regulation (Nio et al., 2017) . The histological assessment in this study was conducted under nonbiased condition, although the quantification method does not fully satisfy the criteria of "Stereological methods" stated in Schmitz & Hof, 2005 . In detail, the ROIs in this study were not identified with the Nissl staining of adjacent sections and were not fully covered with the regularly spaced series of sections. Strict stereological method should have been applied; however, the ROIs in this study were reliably identified using the standard cytoarchitectonic and anatomical landmarks as reported in previous studies (Göktalay & Millington, 2016; Ryan et al., 2014) , and the procedures including the section selection were conducted under blinded conditions.
In conclusion, the present study supposed that BRS-3-expressing neurons regulate energy homeostasis through a novel neuronal pathway in the hypothalamus. Our findings suggested that BRS-3 could be used as a marker of a novel neuronal population associated with energy homeostasis. Still, our hypothesis should be confirmed through more direct methodology, such as optogenetics and DREADD (Designer Receptors Exclusively Activated by Designer Drugs) in the future research. At present, no high-affinity endogenous ligand of BRS-3 has been identified, except for that of the BRS-3 phylogenetic subgroup in Drosophila (Ida et al., 2012; Ikeda et al., 2015; Sano et al., 2015) .
Further study of the BRS-3-related neural pathway, including the deorphanization of BRS-3, is needed to determine the mechanism underlying energy homeostasis and to evaluate BRS-3 as a potential therapeutic target.
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